Uro-BCG MEDAC Germany 1 dose for intravesical administration
Article:
M-10
In Stock
Indications
- — treatment of preinvasive bladder carcinoma (in situ); — prevention of recurrence of preinvasive carcinoma of the bladder (in situ); - prevention of recurrence of non-invasive papillary carcinoma (not extending beyond the mucosa) Ta G1-G2 (for multifocal and / or recurrent tumors) and TaG3; - prevention of recurrence of urothelial carcinoma that has spread to the T1 subepithelial connective tissue (without penetration into the muscle layer of the bladder).
-
Commercial name:Uro-BCG
-
Quantity:one
-
Release form:Dose
No reviews yet